Progestin and adipoQ receptor family member 3 (PAQR3)
Target
PAQR3
Molecular classification
Receptor (membrane protein receptor, part of the PAQR family), Scaffold protein (Golgi-targeted), Seven-transmembrane protein
01
Overview
Progestin and adipoQ receptor family member 3 (PAQR3), also known as Raf kinase trapping to Golgi (RKTG), is a seven-transmembrane protein anchored in the Golgi apparatus, belonging to the PAQR receptor family[1][2][6]. PAQR3 modulates cellular signaling by sequestering Raf-1 kinase to the Golgi, suppressing the Raf/MEK/ERK pathway to regulate cell proliferation, migration, and tumor progression[2][3][7]. It acts as a scaffold for cholesterol biosynthesis by anchoring Scap/SREBP complexes, mediates energy metabolism, influences insulin sensitivity, and plays key roles in inflammation and fibrosis, especially in metabolic disease and diabetic complications[1][4][6]. PAQR3 is recognized as a tumor suppressor gene, downregulated in various cancers, and is being investigated for its potential as a therapeutic target and biomarker in oncology and metabolic disorders[2][4][6].
Other names
PAQR3RKTG (Raf kinase trapping to Golgi)Progestin and adipoQ receptor family member IIIRaf kinase trapping to Golgi
02
Mechanism of action
Inhibition of Raf/MEK/ERK pathway (by sequestration of Raf kinases at the Golgi); Downregulation of SREBP-mediated cholesterol synthesis (by interfering with Scap/SREBP anchoring); Modulation of PI3K and AKT-related pathways (regulation of insulin sensitivity and metabolism).
03
Biological functions
Signal transduction (spatial regulation of Raf/MEK/ERK signaling)Tumor suppression (negative regulation of cell proliferation and migration)Cholesterol biosynthesis regulation (via anchoring Scap/SREBP complex)Modulation of insulin sensitivity and glucose/lipid metabolismRegulation of inflammationRegulation of ubiquitin-mediated proteolysis (modulating PPARA/PPARG degradation)
04
Disease associations
Cancer (tumor suppressor, with established roles in several human cancers and involvement in proliferation and metastasis)Metabolic disorders (regulation of insulin resistance, obesity, and cholesterol homeostasis)Diabetic complications (inflammation and fibrosis in diabetic nephropathy)Liver disorders (steatosis, cholesterol dysfunction)Potential involvement in skin and connective tissue diseases (reported phenotype associations)
05
Safety considerations
Therapeutic targeting is limited by insufficient specificity and knowledge of side effects, given PAQR3’s role in multiple essential cell signaling pathways[2][3][4].Risks may exist if systemic inhibition or activation of PAQR3 disrupts metabolic and proliferative homeostasis (potential for off-target effects, but no detailed safety concerns yet established in human clinical use)[3][4].
06
Interacting drugs
No direct, clinically approved drugs are known to target PAQR3 yet. Its role is primarily studied in genetic and molecular biology research; therefore, interacting agents so far are experimental (e.g., synthetic peptides that disrupt PAQR3-Scap/SREBP interaction)[4].
07
Biomarkers
PAQR3 expression levels (tumor suppression, progression, and prognosis marker in cancers)PAQR3-deficient status in gene knockout or reduction in tissues (cancer and metabolic disease risk)
Beyond the preview
Go deeper on Progestin and adipoQ receptor family member 3 (PAQR3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Progestin and adipoQ receptor family member 3 (PAQR3).